Home > Publications Database > Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study > print

001     154201
005     20240411115839.0
024 7 _ |a pmc:PMC7566134
|2 pmc
024 7 _ |a 10.1186/s13195-020-00701-7
|2 doi
024 7 _ |a altmetric:92662384
|2 altmetric
024 7 _ |a pmid:33066827
|2 pmid
037 _ _ |a DZNE-2021-00063
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Sannemann, Lena
|0 0000-0003-1072-9375
|b 0
|e Corresponding author
245 _ _ |a Neuropsychiatric symptoms in at-risk groups for AD dementia and their association with worry and AD biomarkers—results from the DELCODE study
260 _ _ |a London
|c 2020
|b BioMed Central
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1712757926_11350
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a BackgroundEarly identification of individuals at risk of dementia is mandatory to implement prevention strategies and design clinical trials that target early disease stages. Subjective cognitive decline (SCD) and neuropsychiatric symptoms (NPS) have been proposed as potential markers for early manifestation of Alzheimer’s disease (AD). We aimed to investigate the frequency of NPS in SCD, in other at-risk groups, in healthy controls (CO), and in AD patients, and to test the association of NPS with AD biomarkers, with a particular focus on cognitively unimpaired participants with or without SCD-related worries.MethodsWe analyzed data of n = 687 participants from the German DZNE Longitudinal Cognitive Impairment and Dementia (DELCODE) study, including the diagnostic groups SCD (n = 242), mild cognitive impairment (MCI, n = 115), AD (n = 77), CO (n = 209), and first-degree relatives of AD patients (REL, n = 44). The Neuropsychiatric Inventory Questionnaire (NPI-Q), Geriatric Depression Scale (GDS-15), and Geriatric Anxiety Inventory (GAI-SF) were used to assess NPS. We examined differences of NPS frequency between diagnostic groups. Logistic regression analyses were carried out to further investigate the relationship between NPS and cerebrospinal fluid (CSF) AD biomarkers, focusing on a subsample of cognitively unimpaired participants (SCD, REL, and CO), who were further differentiated based on reported worries.ResultsThe numbers of reported NPS, depression scores, and anxiety scores were significantly higher in subjects with SCD compared to CO. The quantity of reported NPS in subjects with SCD was lower compared to the MCI and AD group. In cognitively unimpaired subjects with worries, low Aß42 was associated with higher rates of reporting two or more NPS (OR 0.998, 95% CI 0.996–1.000, p < .05).ConclusionThese findings give insight into the prevalence of NPS in different diagnostic groups, including SCD and healthy controls. NPS based on informant report seem to be associated with underlying AD pathology in cognitively unimpaired participants who worry about cognitive decline.Trial registrationGerman Clinical Trials Register DRKS00007966. Registered 4 May 2015
536 _ _ |a 342 - Disease Mechanisms and Model Systems (POF3-342)
|0 G:(DE-HGF)POF3-342
|c POF3-342
|f POF III
|x 0
536 _ _ |a 344 - Clinical and Health Care Research (POF3-344)
|0 G:(DE-HGF)POF3-344
|c POF3-344
|f POF III
|x 1
588 _ _ |a Dataset connected to CrossRef
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Alzheimer Disease: epidemiology
|2 MeSH
650 _ 2 |a Anxiety: epidemiology
|2 MeSH
650 _ 2 |a Biomarkers
|2 MeSH
650 _ 2 |a Cognitive Dysfunction: epidemiology
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Longitudinal Studies
|2 MeSH
650 _ 2 |a Neuropsychological Tests
|2 MeSH
693 _ _ |0 EXP:(DE-2719)DELCODE-20140101
|5 EXP:(DE-2719)DELCODE-20140101
|e Longitudinal Cognitive Impairment and Dementia Study
|x 0
700 1 _ |a Schild, Ann-Katrin
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Altenstein, Slawek
|0 P:(DE-2719)2811720
|b 2
700 1 _ |a Bartels, Claudia
|0 P:(DE-2719)9000444
|b 3
700 1 _ |a Brosseron, Frederic
|0 P:(DE-2719)2810593
|b 4
700 1 _ |a Bürger, Katharina
|0 P:(DE-2719)2811351
|b 5
700 1 _ |a Cosma, Nicoleta Carmen
|b 6
700 1 _ |a Fliessbach, Klaus
|0 P:(DE-2719)2811326
|b 7
700 1 _ |a Freiesleben, Silka Dawn
|0 P:(DE-HGF)0
|b 8
700 1 _ |a Glanz, Wenzel
|0 P:(DE-2719)2811614
|b 9
700 1 _ |a Heneka, Michael T.
|0 P:(DE-2719)2000008
|b 10
700 1 _ |a Janowitz, Daniel
|b 11
700 1 _ |a Kilimann, Ingo
|0 P:(DE-2719)2810394
|b 12
700 1 _ |a Kobeleva, Xenia
|0 P:(DE-2719)9001475
|b 13
|u dzne
700 1 _ |a Laske, Christoph
|0 P:(DE-2719)2000055
|b 14
700 1 _ |a Metzger, Coraline D.
|0 P:(DE-2719)9000443
|b 15
700 1 _ |a Munk, Matthias H. J.
|b 16
700 1 _ |a Perneczky, Robert
|0 P:(DE-2719)2812234
|b 17
700 1 _ |a Peters, Oliver
|0 P:(DE-HGF)0
|b 18
700 1 _ |a Polcher, Alexandra
|0 P:(DE-2719)2810925
|b 19
700 1 _ |a Priller, Josef
|0 P:(DE-HGF)0
|b 20
700 1 _ |a Rauchmann, Boris
|b 21
700 1 _ |a Rösch, Christina
|0 P:(DE-HGF)0
|b 22
700 1 _ |a Rudolph, Janna
|0 P:(DE-2719)2812032
|b 23
700 1 _ |a Schneider, Anja
|0 P:(DE-2719)2812035
|b 24
700 1 _ |a Spottke, Annika
|0 P:(DE-2719)2811324
|b 25
700 1 _ |a Spruth, Eike Jakob
|0 P:(DE-HGF)0
|b 26
700 1 _ |a Teipel, Stefan
|0 P:(DE-2719)2000026
|b 27
700 1 _ |a Vukovich, Ruth
|0 P:(DE-HGF)0
|b 28
700 1 _ |a Wagner, Michael
|0 P:(DE-2719)2000057
|b 29
700 1 _ |a Wiltfang, Jens
|0 P:(DE-2719)2811317
|b 30
700 1 _ |a Wolfsgruber, Steffen
|0 P:(DE-2719)2810544
|b 31
700 1 _ |a Düzel, Emrah
|0 P:(DE-2719)2000005
|b 32
700 1 _ |a Jessen, Frank
|0 P:(DE-2719)2000032
|b 33
|e Last author
773 _ _ |a 10.1186/s13195-020-00701-7
|g Vol. 12, no. 1, p. 131
|0 PERI:(DE-600)2506521-X
|n 1
|p 131
|t Alzheimer's research & therapy
|v 12
|y 2020
|x 1758-9193
856 4 _ |u https://alzres.biomedcentral.com/articles/10.1186/s13195-020-00701-7
856 4 _ |u https://pub.dzne.de/record/154201/files/DZNE-2021-00063.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/154201/files/DZNE-2021-00063.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:154201
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)2811720
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9000444
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2810593
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 5
|6 P:(DE-2719)2811351
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 7
|6 P:(DE-2719)2811326
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)2811614
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)2000008
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2810394
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)9001475
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 14
|6 P:(DE-2719)2000055
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 15
|6 P:(DE-2719)9000443
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2812234
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2810925
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 23
|6 P:(DE-2719)2812032
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 24
|6 P:(DE-2719)2812035
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 25
|6 P:(DE-2719)2811324
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 27
|6 P:(DE-2719)2000026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 29
|6 P:(DE-2719)2000057
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 30
|6 P:(DE-2719)2811317
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 31
|6 P:(DE-2719)2810544
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 32
|6 P:(DE-2719)2000005
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 33
|6 P:(DE-2719)2000032
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-342
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Disease Mechanisms and Model Systems
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Erkrankungen des Nervensystems
|1 G:(DE-HGF)POF3-340
|0 G:(DE-HGF)POF3-344
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 1
913 2 _ |a DE-HGF
|b Programmungebundene Forschung
|l ohne Programm
|1 G:(DE-HGF)POF4-890
|0 G:(DE-HGF)POF4-899
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-800
|4 G:(DE-HGF)POF
|v ohne Topic
|x 0
914 1 _ |y 2020
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-08
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2020-08-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-08
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ALZHEIMERS RES THER : 2021
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2021-02-14T16:18:57Z
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2020-08-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2021-02-14T16:18:57Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-08
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-08
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2020-08-27
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b ALZHEIMERS RES THER : 2021
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2020-08-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2022-11-08
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-08
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2020-08-27
920 1 _ |0 I:(DE-2719)6000014
|k Göttingen common
|l Göttingen common
|x 0
920 1 _ |0 I:(DE-2719)1011303
|k AG Heneka ; AG Heneka
|l Neuroinflammation, Biomarker
|x 1
920 1 _ |0 I:(DE-2719)1011101
|k Patient Studies Bonn
|l Patient Studies Bonn
|x 2
920 1 _ |0 I:(DE-2719)1110002
|k AG Höglinger 1
|l Translational Neurodegeneration
|x 3
920 1 _ |0 I:(DE-2719)1510100
|k AG Teipel
|l Clinical Dementia Research (Rostock /Greifswald)
|x 4
920 1 _ |0 I:(DE-2719)1811005
|k AG Endres
|l Interdisciplinary Dementia Research
|x 5
920 1 _ |0 I:(DE-2719)5000034
|k Delcode
|l Delcode
|x 6
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)6000014
980 _ _ |a I:(DE-2719)1011303
980 _ _ |a I:(DE-2719)1011101
980 _ _ |a I:(DE-2719)1110002
980 _ _ |a I:(DE-2719)1510100
980 _ _ |a I:(DE-2719)1811005
980 _ _ |a I:(DE-2719)5000034
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21